Merck & Co. Inc.
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after the company report...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broa...
Latest News
2 days ago · fool.com
Why Merck Stock Flew Higher on FridayThe company easily beat analyst estimates for both revenue and net income. Market players didn't seem overly worried about the future of its top drug.
2 days ago · benzinga.com
Merck One of Top Large-Cap Biopharma Picks-AnalystMerck & Co. Inc. (NYSE:MRK) shares were trading higher on Friday on a continued rally on better-than-expected third-quarter earnings and upbeat fiscal 2026 guidance.
2 days ago · zacks.com
Merck Q3 Earnings Call Highlights Pipeline Progress and Raised OutlookMRK raises its 2026 outlook as KEYTRUDA demand, newer medicines and oncology pipeline breakthroughs support growth despite looming patent and generic pressures.
3 days ago · marketbeat.com
Merck & Co., Inc. Q3 Earnings Call HighlightsMerck & Co., Inc. NYSE: MRK reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset product-specific and market headwinds.
3 days ago · fool.com
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings ReactionNewer drugs are scaling fast enough to offset generic losses. Merck's third-quarter sales rose 5% to about $18.1 billion, but roughly $550 million of that came from the timing of customer purchases, so underlying growth was close to flat.
3 days ago · seekingalpha.com
Merck & Co., Inc. (MRK) Q3 2026 Earnings Call TranscriptMerck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript
3 days ago · zacks.com
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock UpMerck's Q3 earnings and sales beat estimates as Keytruda and newer products drive growth, prompting the company to raise its 2026 earnings outlook.
3 days ago · 247wallst.com
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges HigherMerck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook.
3 days ago · seekingalpha.com
Merck: A Strong Quarter, But It's Time To Take A Step BackIn the third quarter, Merck & Co., Inc.'s revenue grew 8.9% QoQ. Sales of Keytruda+Keytruda Qlex, its PD-1 immune checkpoint inhibitors, reached $8.1 billion, up 5.6% YoY and 2.8% QoQ. Winrevair, its activin signaling inhibitor for pulmonary arterial hypertension, also performed well, generating $694 million in net revenue, up 18% sequentially.
4 days ago · zacks.com
Merck (MRK) Surpasses Q3 Earnings and Revenue EstimatesMerck (MRK) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.58 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MRK